101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 102 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statement of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Parentheticals) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flow link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Nature of business and future operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Collaborations, contracts and licensing agreements link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Accounts Payable and Accrued Liabilities link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Financing link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Concentrations of credit risk link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Contingencies and commitments link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Collaborations, contracts and licensing agreements (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Financing (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Concentrations of credit risk (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Contingencies and commitments (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Nature of business and future operations (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Significant Accounting Policies (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Merger with Arbutus Biopharma Inc. (Formerly OnCore BioPharma, Inc.) (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Collaborations, contracts and licensing agreements (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Financing (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Concentrations of credit risk (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Contingencies and commitments (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 131 - Statement - Fair Value, Assets Measured on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Changes In Fair Value Of Warrants (Details) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Black-Scholes Option-pricing Assumptions (Details) link:calculationLink link:presentationLink link:definitionLink 134 - Statement - Business Acquisition Assets and Liabilties Transferred (Details) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Summary of Acquired Identifiable Intangible Assets (Details) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Pro Forma Financial Information (Details) link:calculationLink link:presentationLink link:definitionLink 137 - Statement - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details) link:calculationLink link:presentationLink link:definitionLink 138 - Statement - Deferred Revenue, by Arrangement, Disclosure (Details) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Schedule of Accounts Payable and Accrued Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink